



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** ☒ HIV-1 ASM 93765 Virus

**Catalog Number:** 2786

**Lot Number:** 06 Apr 95 (D6)

**Release Category:** A

**Provided:** Each isolate is provided as 1 ml cell-free virus.

**Original Source:** These virus stocks originate from clinically and virologically well defined HIV seropositive patients enrolled in the San Francisco AIDS Clinic Cohort. Virus was isolated from either healthy long term positive (HLP) individuals seropositive for >10 years with CD4 counts generally >500/mm<sup>3</sup>, or from recent seroconverters (RSC) seropositive for 500/mm<sup>3</sup>.

**Host Strain:** Human PBMCs

**Sterility:** Negative for bacteria, fungi, and mycoplasma.

**Description:** R5.

**Special Characteristics:** All isolates have been propagated only in PBMCs, and only for a few passages. The viruses may be useful for phenotypic and genotypic characterization of virologic factors that influence the rate of progression of HIV disease.

**Recommended Storage:** Liquid nitrogen.

**Contributor:** Drs. Mark Feinberg and Susan Buchbinder.

**References:** Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Homberg SD. Long-term HIV-1 infection without immunologic progression. *AIDS* **8**:1123-1128, 1994.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 ASM 93765 from Drs. Mark Feinberg and Susan Buchbinder." Also include the reference cited above in any publications.

| Virus     | Cat. No. | Lot               | TCID50/0.2 ml | Type | Co-receptor Usage | Plasma Viral Load (copies/ml) | CD4/mm <sup>3</sup> | CD8/mm <sup>3</sup> |
|-----------|----------|-------------------|---------------|------|-------------------|-------------------------------|---------------------|---------------------|
| ASM 79    | 2784     | 2 14 Apr 95 (D7)  | 1:6208        | RSC  | R5                | 4460                          | 865                 | 1270                |
| ASM 34    | 2785     | 2 5 Apr 95 (D5)   | 1:57,052      | HLP  | R5                | 43,000                        | 375                 | 1922                |
| ASM 93765 | 2786     | 2 6 Apr 95 (D6)   | 1:43,238      | HLP  | R5                | 1150                          | 769                 | 915                 |
| ASJM 108  | 2787     | 2 6 Apr 95 (D6)   | 1:18,820      | HLP  | R5                | 148,000                       | 449                 | 758                 |
| ASM 80    | 2788     | 2 6 Apr 95 (D6)   | 1:57,052      | RSC  | R5                | 94,000                        | 427                 | 1325                |
| ASM 94122 | 2789     | 2 7 Apr 95 (D7)   | 1:8192        | HLP  | R5                | 59,000                        | 553                 | 656                 |
| ASM 57    | 2790     | 2 13 Apr 95 (D6)  | 1:32,768      | HLP  | R5                | 110,000                       | 1083                | 1054                |
| ASM 44    | 2791     | 2 6 Apr 95 (D6)   | 1:10,809      | RSC  | R5X4              | 203,000                       | 531                 | 1054                |
| ASM 3     | 2792     | 2 14 Apr 95 (D7)  | 1:1552        | HLP  | R5                |                               | 1066                | 956                 |
| ASM 3     | 2792     | 3 17 Apr 95 (D10) | 1:1552        | HLP  | R5                |                               | 1066                | 956                 |
| ASM 61    | 2793     | 2 6 Apr 95 (D6)   | 1:24,834      | HLP  | R5                | 42,000                        | 886                 | 675                 |
| ASM 71    | 2794     | 2 14 Apr 95 (D7)  | 1:2702        | HLP  | R5                | 273                           | 934                 | 837                 |
| ASM 54    | 2795     | 2 13 Apr 95 (D6)  | 1:4705        | RSC  | R5X4              |                               | 483                 | 1154                |
| ASM 121   | 2796     | 2 13 Apr 95 (D6)  | 1:1176        | HLP  | R5                | 1193                          | 782                 | 1865                |
| ASM 42    | 2797     | 2 13 Apr 95 (D6)  | 1:10,809      | RSC  | R5                | 1227                          | 661                 | 1338                |
| ASM 93534 | 2798     | 2 14 Apr 95 (D7)  | 1:2702        | HLP  | R5                |                               | 1378                | 1378                |

### Propagation of ASM Viruses

#### Reagent

*PHA Medium*

RPMI 1640 supplemented with L-glutamine, 20% heat-inactivated fetal bovine serum, 3% natural IL-2 (Boehringer Mannheim or equivalent), 5 µg/ml PHA-P (Sigma or equivalent), and 50 µg/ml gentamicin

*Culture Medium*

RPMI 1640 supplemented with L-glutamine, 20% heat-inactivated fetal bovine serum, 5% natural IL-2 (Boehringer Mannheim or equivalent), and 50 µg/ml gentamicin

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

### ***Propagation***

1. Stimulate a mixture of PMBCs from two donors ( $2 \times 10^6$  cells/ml) in PHA Medium for 24 hours.
2. Resuspend donor cells ( $2 \times 10^6$  cells/ml) in Culture Medium. Add 0.5 ml of stock virus to 10 ml of culture medium containing  $2 \times 10^7$  freshly stimulated PBMCs in a 15 ml culture tube, and incubate overnight.
3. Wash the cells twice with PBS-CMF. Resuspend the cell pellet in 40 ml Culture Medium containing  $6 \times 10^7$  freshly stimulated PBMCs, and transfer the infected cells to a tissue culture flask.
4. Replace half of the medium with fresh Culture Medium every third day, and with fresh Culture Medium containing freshly stimulated PBMCs every seventh day. Monitor p24 antigen levels every 3-4 days.

**Last Updated:** July 30, 2018

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.